We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Idenix Resumes HCV Drug Trials, Faces Hold on HIV Treatment
Idenix Resumes HCV Drug Trials, Faces Hold on HIV Treatment
February 16, 2011
The FDA has reduced a full clinical hold to a partial one for Idenix Pharmaceuticals’ hepatitis C (HCV) treatment IDX184, but it instituted a clinical hold on an HIV candidate over seizure concerns.